|
1
|
Schiødt FV and Lee WM: Fulminant liver
disease. Clin Liver Dis. 7:331–349. 2003.
|
|
2
|
Mukherjee S, Mahmoudi TM and Mukherjee U:
Liver transplant for viral hepatitis and fulminant hepatic failure.
Minerva Gastroenterol Dietol. 55:83–100. 2009.PubMed/NCBI
|
|
3
|
Xing WW, Zou MJ, Liu S, Xu T, Gao J, Wang
JX and Xu DG: Hepatoprotective effects of IL-22 on fulminant
hepatic failure induced by d-galactosamine and lipopolysaccharide
in mice. Cytokine. 56:174–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shin JW, Wang JH, Park HJ, Choi MK, Kim HG
and Son CG: Herbal formula CGX ameliorates
LPS/D-galactosamine-induced hepatitis. Food Chem Toxicol.
49:1329–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeong YI, Jung ID, Lee CM, et al: The
novel role of platelet-activating factor in protecting mice against
lipopolysaccharide-induced endotoxic shock. PLoS One. 4:e65032009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thirunavukkarasu C, Uemura T, Wang LF,
Watkins SC and Gandhi CR: Normal rat hepatic stellate cells respond
to endotoxin in LBP-independent manner to produce inhibitor(s) of
DNA synthesis in hepatocytes. J Cell Physiol. 204:654–665. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fisher JW: Erythropoietin: physiology and
pharmacology update. Exp Biol Med (Maywood). 228:1–14.
2003.PubMed/NCBI
|
|
8
|
Coleman T and Brines M: Science review:
recombinant human erythropoietin in critical illness: a role beyond
anemia? Crit Care. 8:337–341. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sepodes B, Maio R, Pinto R, et al:
Recombinant human erythropoietin protects the liver from hepatic
ischemia-reperfusion injury in the rat. Transpl Int. 19:919–926.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis LD: Preclinical and clinical
studies: a preview of potential future applications of
erythropoietic agents. Semin Hematol. 41(4 Suppl 7): 17–25. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kadota T, Shingo T, Yasuhara T, et al:
Continuous intraventricular infusion of erythropoietin exerts
neuroprotective/rescue effects upon Parkinson’s disease model of
rats with enhanced neurogenesis. Brain Res. 1254:120–127.
2009.PubMed/NCBI
|
|
12
|
Mammis A, McIntosh TK and Maniker AH:
Erythropoietin as a neuroprotective agent in traumatic brain injury
Review. Surg Neurol. 71:527–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lippi G, Franchini M and Banfi G:
Biochemistry and physiology of anabolic androgenic steroids doping.
Mini Rev Med Chem. 11:362–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dimitrijevic ZM, Cvetkovic TP, Djordjevic
VM, et al: How the duration period of erythropoietin treatment
influences the oxidative status of hemodialysis patients. Int J Med
Sci. 9:808–815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akisu M, Küllahçioğlu Girgin F, Baka M,
Hüsseyinov A and Kültürsay N: The role of recombinant human
erythropoietin in lipid peroxidation and platelet-activating factor
generation in a rat model of necrotizing enterocolitis. Eur J
Pediatr Surg. 11:167–172. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nairz M, Sonnweber T, Schroll A, Theurl I
and Weiss G: The pleiotropic effects of erythropoietin in infection
and inflammation. Microbes Infect. 14:238–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang CW, Li C, Jung JY, et al:
Preconditioning with erythropoietin protects against subsequent
ischemia-reperfusion injury in rat kidney. FASEB J. 17:1754–1755.
2003.PubMed/NCBI
|
|
18
|
Chong ZZ, Kang JQ and Maiese K:
Hematopoietic factor erythropoietin fosters neuroprotection through
novel signal transduction cascades. J Cereb Blood Flow Metab.
22:503–514. 2002. View Article : Google Scholar
|
|
19
|
Kudo H, Takahara T, Yata Y, Kawai K, Zhang
W and Sugiyama T: Lipopolysaccharide triggered TNF-alpha-induced
hepatocyte apoptosis in a murine non-alcoholic steatohepatitis
model. J Hepatol. 51:168–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuhla A, Eipel C, Abshagen K, Siebert N,
Menger MD and Vollmar B: Role of the perforin/granzyme cell death
pathway in D-Gal/LPS-induced inflammatory liver injury. Am J
Physiol Gastrointest Liver Physiol. 296:G1069–G1076. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda T, Abe K, Kuroda N, et al: The
inhibition of apoptosis by glycyrrhizin in hepatic injury induced
by injection of lipopolysaccharide/D-galactosamine in mice. Arch
Histol Cytol. 71:163–178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen JC, Ng CJ, Chiu TF and Chen HM:
Altered neutrophil apoptosis activity is reversed by melatonin in
liver ischemia-reperfusion. J Pineal Res. 34:260–264. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jaeschke H: Reactive oxygen and mechanisms
of inflammatory liver injury: Present concepts. J Gastroenterol
Hepatol. 26(Suppl 1): 173–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han D, Hanawa N, Saberi B and Kaplowitz N:
Hydrogen peroxide and redox modulation sensitize primary mouse
hepatocytes to TNF-induced apoptosis. Free Radic Biol Med.
41:627–639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou W, Roth RA, Younis HS, Burgoon LD and
Ganey PE: Oxidative stress is important in the pathogenesis of
liver injury induced by sulindac and lipopolysaccharide
cotreatment. Toxicology. 272:32–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan X and van Bel F: Pharmacological
neuroprotection after perinatal asphyxia. J Matern Fetal Neonatal
Med. 23(Suppl 3): 17–19. 2010. View Article : Google Scholar
|
|
27
|
Shang Y, Li X, Prasad PV, et al:
Erythropoietin attenuates lung injury in lipopolysaccharide treated
rats. J Surg Res. 155:104–110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cetin H, Olgar S, Oktem F, Ciris M, Uz E,
Aslan C and Ozguner F: Novel evidence suggesting an anti-oxidant
property for erythropoietin on vancomycin-induced nephrotoxicity in
a rat model. Clin Exp Pharmacol Physiol. 34:1181–1185.
2007.PubMed/NCBI
|
|
29
|
Guneli E, Cavdar Z, Islekel H, et al:
Erythropoietin protects the intestine against ischemia/reperfusion
injury in rats. Mol Med. 13:509–517. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oztürk E, Demirbilek S, Köroğlu A, et al:
Propofol and erythropoietin antioxidant properties in rat brain
injured tissue. Prog in Neuropsychopharmacol Biol Psychiatry.
32:81–86. 2008.PubMed/NCBI
|
|
31
|
Brines M and Cerami A: Emerging biological
roles for erythropoietin in the nervous system. Nat Rev Neurosci.
6:484–494. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brines M, Grasso G, Fiordaliso F, et al:
Erythropoietin mediates tissue protection through an erythropoietin
and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA.
101:14907–14912. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meier R, Alessi DR, Cron P, Andjelković M
and Hemmings BA: Mitogenic activation, phosphorylation, and nuclear
translocation of protein kinase Bbeta. J Biol Chem.
272:30491–30497. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim AH, Khursigara G, Sun X, Franke TF and
Chao MV: Akt phosphorylates and negatively regulates apoptosis
signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abdelrahman M, Sharples EJ, McDonald MC,
Collin M, Patel NS, Yaqoob MM and Thiemermann C: Erythropoietin
attenuates the tissue injury associated with hemorrhagic shock and
myocardial ischemia. Shock. 22:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
